As more federal and state lawmakers consider importing lower-cost medicines from Canada, the U.S. Food and Drug Administration warned one of the largest Canadian brokers for violating interstate commerce by sending unapproved and misbranded drugs to Americans.
In a Feb. 26 warning letter to CanaRx, the agency wrote that substituting FDA-approved drugs with unapproved medicines “poses significant health risks to U.S. consumers.” The FDA argued the broker sells drugs subject to a safety program that restricts distribution; some medicines made overseas may have escaped FDA recall procedures; and some drugs have different trade names or dosages.
About the Author Reprints
